-- 根據《日經新聞》週三報道，日本同意從阿聯酋額外購買2,000萬桶原油，以應對霍爾木茲海峽附近海域的供應中斷，並尋求其他替代供應路線。 該協議是在經濟大臣赤澤亮生與阿聯酋工業部長蘇爾坦·賈比爾在阿布達比舉行會談後達成的。報道稱，赤澤亮生表示，他已請求阿聯酋向日本增發原油。 根據2025年的消費水準計算，這批額外的原油大約可以滿足日本八到九天的石油需求。報導稱，部分原油預計將經由阿曼灣的富查伊拉港運輸，從而避開霍爾木茲海峽。 日本約40%的原油進口來自阿聯酋，隨著中東局勢日益緊張，日本一直在尋求其他供應管道。報導也指出，東京上個月也從墨西哥獲得了100萬桶原油。 （市場動態新聞來自與全球市場專業人士的對話。這些資訊據信來自可靠來源，但可能包含傳聞和推測。準確性無法保證。）
Related Articles
Asia
StarHub's Net Attributable Profit Falls 81% in Q1
StarHub's (SGX:CC3) net attributable profit to shareholders plunged 81% in the first quarter of the year to SG$5.9 million from SG$31.8 million a year earlier, according to a Thursday filing with the Singapore Exchange.Revenue declined 6.1% year over year to SG$507.3 million from SG$540.5 million, mainly due to an across-the-board decline in services revenue.
$SGX:CC3
Asia
Meesho Narrows Consolidated Loss in Fiscal Q4
Meesho (NSE:MEESHO, BOM:544632) narrowed its consolidated attributable loss to 1.66 billion Indian rupees in the fiscal fourth quarter ended March 31, from a loss of 13.9 billion rupees a year ago.Loss per share contracted to 0.36 rupees from a loss per share of 3.39 rupees a year earlier, the online marketplace said in a filing to the Indian stock exchanges on Wednesday. The loss per share was lower than the 0.73 rupees estimated by the analysts polled by Visible Alpha.Revenue from operations in fiscal Q4 increased to 35.3 billion rupees from 24.0 billion rupees a year ago. This is a tad higher than Visible Alpha's estimate of 35.2 billion rupees a year ago.
$BOM:544632$NSE:MEESHO
Asia
Changchun High-Tech Gets Regulatory Nod for Gouty Arthritis Drug
Changchun High-Tech Industry (SHE:000661) subsidiary Changchun Genescience Pharmaceutical obtained China's regulatory approval to manufacture and market its fuxinqibai monoclonal antibody injection.The drug is indicated for acute gouty arthritis attacks in adults poorly responsive to standard therapies, according to a Thursday filing with the Shenzhen bourse.
$SHE:000661